GlassScriptPhysician profile
Sean Kevin Mcveigh
NPI 1497749378
$3,256.35
in general payments reported to CMS, 2019-2025
25 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $781 · 2021: $641 · 2022: $198 · 2023: $66.02 · 2024: $248 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $274 · Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $273.93 |
| Food and Beverage | $184.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $903.85 | 2019-2024 | Tezspire |
| Glaxosmithkline, LLC. | $723.99 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $193.94 | 2024 | |
| Genzyme Corporation | $119.51 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $111.08 | 2019-2020 | |
| Grifols USA, LLC | $99.16 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $97.11 | 2019-2024 | (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $95.29 | 2019-2021 | |
| Genentech USA, INC. | $86.15 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $79.99 | 2025 | Uptravi, Opsumit |
| Advanced Respiratory, INC | $56.79 | 2019-2020 | |
| Aerin Medical INC. | $36.19 | 2025 | |
| Abbvie INC. | $34.47 | 2021-2022 | |
| Vapotherm INC | $33.49 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $33.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32.54 | 2020-2021 | |
| Mylan Specialty L.P. | $28.61 | 2019-2020 | |
| Circassia INC. | $27.16 | 2019 | |
| Merck Sharp & Dohme LLC | $25.08 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $19.52 | 2019 | |
| Pulmonx Corporation | $18.93 | 2021 | |
| Allergan, INC. | $16.60 | 2019 | |
| Olympus America INC. | $15.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mcveigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.